Última actualización 12 de septiembre de 2026
Key finding
The primary end point is the proportion of participants achieving glycated hemoglobin (HbA1c) <7.0% at year 1.
The SEPRA trial compared once-weekly subcutaneous semaglutide to standard care in adults with type 2 diabetes, assessing various health outcomes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The SEPRA trial compared once-weekly subcutaneous semaglutide to standard care in adults with type 2 diabetes, assessing various health outcomes.
Understanding the effectiveness of semaglutide in comparison to standard care is crucial for clinicians and patients in making informed treatment decisions for type 2 diabetes. If proven effective, semaglutide could offer a new option for better glycemic control and weight management, potentially improving overall health outcomes for patients.
Effectiveness of interventions remains unclear due to insufficient data. Study design may limit generalizability to broader populations. Limited information on long-term outcomes beyond one year.
Published in
Publication details and source links for this paper.
John BB, Helene NC, Brian JH, et al. SEmaglutide PRAgmatic (SEPRA): A Pragmatic Trial Comparing Semaglutide to Standard Care in Adults with Type 2 Diabetes. BMJ Open Diabetes Research & Care. 2023;11(3):e003206. doi:10.1136/bmjdrc-2022-003206
The proportion of participants achieving HbA1c <7.0% was evaluated as a primary outcome.
Glycemic control was assessed as a key outcome for both semaglutide and standard care.
Weight loss was measured as an important secondary outcome.
Patient-reported outcomes were included to gauge participant satisfaction.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Subcutaneous Semaglutide and Frequency of physician visits, Patient-reported outcomes, Proportion achieving HbA1c <7.0%, and 1 more.
This study contributes evidence to
Primary intervention
Subcutaneous Semaglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
4
Evidence pairs
703
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Subcutaneous Semaglutide → Frequency of physician visits
Subcutaneous Semaglutide → Frequency of physician visits
Subcutaneous Semaglutide → Patient-reported outcomes
Subcutaneous Semaglutide → Patient-reported outcomes
Subcutaneous Semaglutide → Proportion achieving HbA1c <7.0%
Subcutaneous Semaglutide → Proportion achieving HbA1c <7.0%
Subcutaneous Semaglutide → Weight loss dependent effect on HbA1c
Subcutaneous Semaglutide → Weight loss dependent effect on HbA1c
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Subcutaneous Semaglutide and Frequency of physician visits, Subcutaneous Semaglutide and Patient-reported outcomes.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Frequency of physician visits
Measures Frequency of physician visits as a key outcome.
All studies measuring Patient-reported outcomes
Measures Patient-reported outcomes as a key outcome.
All studies on Subcutaneous Semaglutide
Contributes to Subcutaneous Semaglutide evidence base.
All studies measuring Weight loss dependent effect on HbA1c
Measures Weight loss dependent effect on HbA1c as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Subcutaneous Semaglutide appears to improve frequency of physician visits.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Frequency of physician visits
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Subcutaneous Semaglutide for patient-reported outcomes.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Patient-reported outcomes
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Subcutaneous Semaglutide for proportion achieving HbA1c <7.0%.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Proportion achieving HbA1c <7.0%
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear effect of Subcutaneous Semaglutide on weight loss dependent effect on HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Weight loss dependent effect on HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
